NCT07064512

Brief Summary

This study is the first to examine the effects of core temperature elevation on kynurenine pathway (KP) metabolites in healthy young males. It was hypothesized that rise in core temperature due to both pasive heating and exercise will initiate a stress response, affecting the concentration of KP metabolites. Additionally, it was expected that the exercise would produce more pronounced effects due to the increased cardiovascular, mechanical, and metabolic demands associated with it. Thus, the the main purpose of the present study was to investigate and to compare the effects of two distinct heat stress modalities on KP metabolites.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
11

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jan 2021

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 11, 2021

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 12, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 12, 2021

Completed
4.3 years until next milestone

First Submitted

Initial submission to the registry

July 11, 2025

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 14, 2025

Completed
Last Updated

July 17, 2025

Status Verified

July 1, 2025

Enrollment Period

2 months

First QC Date

July 11, 2025

Last Update Submit

July 14, 2025

Conditions

Outcome Measures

Primary Outcomes (9)

  • Change in plasma metabolites of the kynurenine pathway (μm)

    An ultra-performance liquid chromatography-tandem mass spectrometry system (UPLC-MS/MS) was used to measure venous plasma levels of tryptophan, kynurenine, kynurenic acid, 3-hydroxy-kynurenine, quinolinic acid, nicotinamide and picolinic acid (in μm). The UPLC-MS/MS system uses a Xevo TQ-XS triple quadrupole mass spectrometer (Waters) with a Z-spray electrospray interface, and the system operates in electrospray positive multiple reaction monitoring mode.

    Day 1 (every 0.5 °C until rectal temperature (Trec) reached 39°C, followed by a recovery phase until Trec reached 37.5°C)

  • Rectal temperature (°C)

    Rectal temperature (in °C) was measured using a thermocouple (Rectal Probe, Ellab, Denmark) inserted to a depth of 12 cm past the anal sphincter.

    Day 1 (during both heating modalities until Tre reached 39°C, followed by a recovery phase until Trec reached 37.5°C)

  • Change in heart rate (bpm)

    Heart rate (in bpm) was recorded using a heart rate sensor with a chest strap (Polar, Finland).

    Day 1 (during both heating modalities until Tre reached 39°C, followed by a recovery phase until Trec reached 37.5°C)

  • Change in physiological strain index

    A physiological strain index (PSI) was used to indicate heat strain. PSI = 5 x (Tret - Tre0) x (39.5 - Tre0)\^-1+ 5 x (HRt - HR0) x (180 - HR0)\^-1, where rectal temperature (Tre) t and heart rate (HR) t are simultaneous measurements taken every 0.5°C of the heat exposure and Tre0 and HR0 are the initial measurements.

    Day 1 (every 0.5 °C until rectal temperature (Trec) reached 39°C, followed by a recovery phase until Trec reached 37.5°C)

  • Change in glucose (mmol/L)

    The glucose concentration (in mmol/L) was measured using an automatic blood glucose meter Glucocard X-mini-Plus (Arkray Inc, Japan).

    Day 1 (every 0.5 °C until rectal temperature (Trec) reached 39°C, followed by a recovery phase until Trec reached 37.5°C)

  • Change in lactate (mmol/L)

    The lactate concentration (in mmol/L) was measured using an Accutrend Plus System (Roche, Germany).

    Day 1 (every 0.5 °C until rectal temperature (Trec) reached 39°C, followed by a recovery phase until Trec reached 37.5°C)

  • Changes in prolactin concentration (ng/mL)

    The venous prolactin (in ng/mL) was measured using enzyme-linked immunosorbent assay kit and a Spark multimode microplate reader (Tecan, Austria).

    Day 1 (every 0.5 °C until rectal temperature (Trec) reached 39°C, followed by a recovery phase until Trec reached 37.5°C)

  • Changes in catecholamines concentration (ng/mL)

    The venous adrenaline and noradrenaline concentrations (in ng/mL) was measured using enzyme-linked immunosorbent assay kits and a Spark multimode microplate reader (Tecan, Austria).

    Day 1 (every 0.5 °C until rectal temperature (Trec) reached 39°C, followed by a recovery phase until Trec reached 37.5°C)

  • Changes in salivary cortisol concentration (µg/dL)

    The saliva samples was collected to measure cortisol level (in µg/dL) using an ELISA kits and a Spark multimode microplate reader (Tecan, Austria).

    Day 1 (every 0.5 °C until rectal temperature (Trec) reached 39°C, followed by a recovery phase until Trec reached 37.5°C)

Study Arms (2)

Exogenous heating

EXPERIMENTAL

Healthy young subjects participated received exogenous heating modality, where the participants sat immersed in a water bath at 43.5 ± 0.5°C and remained submerged until rectal temperature reached 39°C.

Other: Exogenous heating

Endogenous heating

EXPERIMENTAL

Healthy young subjects participated received endogenous heating modality, the participant cycled at 60% of his VO2max until rectal temperature reached 39°C

Other: Endogenous heating

Interventions

Exercise was used as the endogenous heating modality, the participant cycled at 60% of his VO2max until rectal temperature reached 39°C

Endogenous heating

Hot-water immersion was used as the exogenous heating modality, where the participants sat immersed in a water bath at 43.5 ± 0.5°C and remained submerged until rectal temperature reached 39°C.

Exogenous heating

Eligibility Criteria

Age18 Years - 36 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • healthy adults;
  • age between 18 - 36 years;
  • physically active (exercising 2-3 times per week);
  • non-smoking.

You may not qualify if:

  • a body mass index (BMI) \> 30 kg/m2;
  • neurological, cardiovascular, metabolic, and/or inflammatory diseases, or conditions that could be worsened by exposure to interventions and that could affect experimental variables;
  • involvement in temperature manipulation program for ≥ 3 months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Lithuanian Sports University

Kaunas, Lithuania

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 11, 2025

First Posted

July 14, 2025

Study Start

January 11, 2021

Primary Completion

March 12, 2021

Study Completion

March 12, 2021

Last Updated

July 17, 2025

Record last verified: 2025-07

Locations